AVALO THERAPEUTICS, INC. (AVTX) Free cash flow 2016–2023
AVALO THERAPEUTICS, INC. (AVTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$30.7MFY2023 · since FY2016: -$14.6M → -$30.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$30.7M | -14.3% |
| FY2022 | -$26.8M | +62.2% |
| FY2021 | -$71.0M | -74.9% |
| FY2020 | -$40.6M | -109.3% |
| FY2019 | -$19.4M | -425.3% |
| FY2018 | -$3.7M | -129.4% |
| FY2017 | $12.6M | +185.9% |
| FY2016 | -$14.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Gross marginAVTX Operating incomeAVTX Operating marginAVTX Operating cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →